POPULARITY
160 episodes with ramez
4 episodes with ramez
3 episodes with ramez
2 episodes with ramez
3 episodes with ramez
2 episodes with ramez
3 episodes with ramez
2 episodes with ramez
2 episodes with ramez
2 episodes with ramez
2 episodes with ramez
2 episodes with ramez
2 episodes with ramez
3 episodes with ramez
15 episodes with ramez
2 episodes with ramez
2 episodes with ramez
3 episodes with ramez
In this episode, hosts Tait Duryea and Ryan Gibson welcome Ramez Fakhoury from IRA Club. This episode dives into how pilots can unlock old 401(k)s, TSPs, and HSAs for real estate and other alternative investments. Hear a detailed story of a Southwest pilot transitioning to American Airlines and learn what decisions made the biggest impact. Whether you're changing airlines or just seeking better returns, this episode is packed with actionable insights.Ramez Fakhoury is the Vice President of IRA Club, a leading self-directed IRA custodian. With a background in hospitality and entrepreneurship, Ramez discovered a passion for alternative investing and now helps individuals unlock their retirement capital for real estate and other private assets. His practical approach and deep knowledge make complex financial strategies accessible for pilots and high-income earners.Show notes:(0:00) Intro(01:07) Introduction to Ramez and IRA Club(04:49) Three options when leaving an airline(06:11) True vs. false self-direction explained(10:27) Why you shouldn't rush rollover decisions(14:39) What you can't invest in with IRAs(20:48) Why IRA Club's structure stands out(27:42) Contribution limits vs. rollover power(38:56) Partnering personal and retirement funds(46:59) Real estate in IRAs: tax pros and cons(51:20) OutroConnect with Ramez:Website: https://www.iraclub.com/LinkedIn: https://www.linkedin.com/company/the-ira-club/ — You've found the number one resource for financial education for aviators! Please consider leaving a rating and sharing this podcast with your colleagues in the aviation community, as it can serve as a valuable resource for all those involved in the industry.Remember to subscribe for more insights at PassiveIncomePilots.com! https://passiveincomepilots.com/ Join our growing community on Facebook: https://www.facebook.com/groups/passivepilotsCheck us out on Instagram @PassiveIncomePilots: https://www.instagram.com/passiveincomepilots/Follow us on X @IncomePilots: https://twitter.com/IncomePilotsGet our updates on LinkedIn: https://www.linkedin.com/company/passive-income-pilots/Do you have questions or want to discuss this episode? Contact us at ask@passiveincomepilots.com See you on the next one!*Legal Disclaimer*The content of this podcast is provided solely for educational and informational purposes. The views and opinions expressed are those of the hosts, Tait Duryea and Ryan Gibson, and do not reflect those of any organization they are associated with, including Turbine Capital or Spartan Investment Group. The opinions of our guests are their own and should not be construed as financial advice. This podcast does not offer tax, legal, or investment advice. Listeners are advised to consult with their own legal or financial counsel and to conduct their own due diligence before making any financial decisions.
The Get Paid Podcast: The Stark Reality of Entrepreneurship and Being Your Own Boss
Dr. Ramez "Mez" Antoun, PT, DPT, OMT, shares the process behind growing his online course business from "should I shut this down?" to "this one launch made more than my entire last year." You'll hear how working with Claire and Sarah Lucille in Get Paid Marketing helped him leverage paid ads, rebuild his messaging, and see exactly how to scale sustainably. If you've wondered whether your niche is too small to succeed with ads, or doubted whether your business can scale, listen to Mez's story! This Week on the Get Paid Podcast: The exact strategies from GPM that helped him consistently grow his list and book cold sales How he cut his cost per lead in half The mindset practices that helped him stay resilient during launch challenges How he doubled his revenue without doubling his client load How paid ads finally gave him proof that strangers wanted what he was selling How working with Claire and Sarah Lucille helped him shift his messaging from explaining the process to selling the outcome (a game-changing move) How GPM helped Mez not just build a better business, but improve his personal life through stronger communication and confidence Mentioned in this podcast: https://www.instagram.com/spine_pt_university/ https://www.spineptuniversity.com/ https://clairepells.com/getpaid https://clairepells.com/afa Now it's time to GET PAID Thanks for tuning into the Get Paid Podcast! If you enjoyed today's episode, head over to Apple Podcasts to subscribe, rate, and leave your honest review. Connect with me on Facebook, YouTube, and Instagram, visit my website for even more detailed strategies, and be sure to share your favorite episodes on social media. Now, it's time to go get yourself paid
In today's episode, we invited experts from across oncology specialties to discuss the long-term effects of the COVID-19 pandemic—the onset of which occurred 5 years ago. Our guests shared how the pandemic's lingering effects continue to shape patient care. We heard from: Ramez N. Eskander, MD, a gynecologic oncologist and assistant professor of obstetrics, gynecology, and reproductive sciences at the University of California San Diego Health Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York Benjamin Herzberg, MD, an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York Kelly McCann, MD, PhD, an assistant professor and breast medical oncologist at UCLA Health's David Geffen School of Medicine in Los Angeles, California Gregory Roloff, MD, a hematologist/oncologist at the University of Chicago Medicine in Illinois
Our guest in this episode, Ramez Naam, is described on his website as “climate tech investor, clean energy advocate, and award-winning author”. But that hardly starts to convey the range of deep knowledge that Ramez brings to a wide variety of fields. It was his 2013 book, “The Infinite Resource: The Power of Ideas on a Finite Planet”, that first alerted David to the breadth of scope of his insight about future possibilities – both good possibilities and bad possibilities. He still vividly remembers its opening words, quoting Charles Dickens from “The Tale of Two Cities”:Quote: “‘It was the best of times; it was the worst of times' – the opening line of Charles Dickens's 1859 masterpiece applies equally well to our present era. We live in unprecedented wealth and comfort, with capabilities undreamt of in previous ages. We live in a world facing unprecedented global risks—risks to our continued prosperity, to our survival, and to the health of our planet itself. We might think of our current situation as ‘A Tale of Two Earths'.” End quote.12 years after the publication of “The Infinite Resource”, it seems that the Earth has become even better, but also even worse. Where does this leave the power of ideas? Or do we need more than ideas, as ominous storm clouds continue to gather on the horizon?Selected follow-ups:Ramez Naam - personal websiteThe Infinite Resource: The Power of Ideas on a Finite PlanetThe Nexus Trilogy (Nexus Crux Apex)Jesse Jenkins (Princeton)Six Degrees: Our Future on a Hotter Planet - book by Mark Lynas1991 eruption of Mount Pinatubo - WikipediaWe cool Earth, with reflective clouds - Make SunsetsDirect Air Capture (DAC) - WikipediaFrontier: An advance market commitment to accelerate carbon removalToward a Responsible Solar Geoengineering Research Program - by David KeithSouth Korea scales down plans for nuclear powerMicrosoft chooses infamous nuclear site for AI powerMachines of Loving Grace: How AI Could Transform the World for the Better - Essay by Dario AmodeiMusic: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain DeclarationPromoguy Talk PillsAgency in Amsterdam dives into topics like Tech, AI, digital marketing, and more drama...Listen on: Apple Podcasts Spotify
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
Lauren Wells teams up with Ramez Fakhoury of the IRA Club to explore the benefits of self-directed IRAs and how they can help you take control of your retirement investments. Learn about diversifying beyond traditional stocks and bonds, and discover how you can make smarter investment choices with your retirement savings. Whether you're new to self-directed IRAs or looking for ways to maximize your current investments, this episode provides valuable insights into unlocking new opportunities and ensuring financial growth for your future.Love the show? Subscribe, rate, review, and share! https://7einvestments.com/podcast/
Hoe groei je van één snackbar naar het domineren van de Amsterdamse horeca met 35 zaken? Tijdens mijn gesprek met Ramez Ramzy werd mij weer duidelijk hoe belangrijk het is om te werken naar die stip op de horizon
durée : 00:03:24 - Le tournoi de golf solidaire à Marcilly-en-Vilette avec Ramez Ghadri - Ramez Ghadri fait partie de l'ordre international des Anysetiers sur la partie Orléans-Sologne, il vient présenter ce tournoi de golf solidaire au golf de Marcilly-en-Villette prévu ce dimanche 2 juin.
In this episode, Dr Elgammal introduces us to The Coretec Group and where it fits into the emerging Advanced Air Mobility market. He tells us about the advantages of silicon anodes and why they are critical to eVTOL aircraft development, plus gives us an idea at what stage the industry is at when it comes to batteries for electric aircraft - especially with some companies targeting commercial operations as early as 2026. We talk about the various projects the Coretec Group is working on, and what can be done to minimise the environmental impact on eVTOL production. And finally, we discuss the efficient and lightweight energy storage solutions to improve efficiency, extend flight range and boost overall performance.
Ramez Fakhoury is an entrepreneur with over two decades of experience in diverse sectors such as hospitality, financial services, and real estate. Serving as the Vice President of the IRA Club, his primary goal is to open opportunities for investors. Ramez is deeply committed to educating and inspiring individuals, empowering them to venture beyond conventional paths and diversify their investments through the power of self-direction. https://www.iraclub.com/partner/multifamily-ap360/Support the showhttps://www.buzzsprout.com/1187780/supporters/newFollow Rama on socials!LinkedIn | Meta | Twitter | Instagram|YoutubeConnect to Rama Krishnahttps://calendly.com/rama-krishna/ E-mail: info@ushacapital.comWebsite: www.ushacapital.comRegister for Multifamily AP360 - 2024 Capital Raising virtual conference - https://multifamilyap360.mykajabi.com/capitalRaisingTo find out more about partnering or investing in a multifamily deal: email: info@ushacapital.com
Nick, Quincy Lee, the CEO of Electric Era, and Ramez Naam, a highly experienced climate tech and energy analyst and investor, dive deep on all things energy and electrification in 2024. Starting with a focus on mobility and the power sector, Quincy, Mez, and Nick touch on topics as far reaching as geoengineering, the power of narratives, and their expectations for decarbonization across other sectors out to 2050 and beyond.Why decarbonization and electrification need to be led by product superiorityWhat to expect in energy and electrification in 2024 and beyondOther trends and topics beyond transportation and the power sector worth your attention Don't miss out on this podcast if you're interested in learning more about the state of climate tech, electrification, and energy broadly, and more! Subscribe on Spotify, Apple, Google, or your favorite podcast platform to catch all the latest episodes.Timestamps:00:05:00 - Mobility and Electrification Outlook for 202400:13:27 - Battery Energy Storage on Grids00:19:19 - One Story of the Decade: Grid Overhaul00:31:27 - The Winning Technologies in Energy Generation00:39:52 - Transitions from ‘Old' to ‘New' Energy Sources00:43:58 - Why Better Products Win in The Energy Transition00:47:00 - Why More Focus on Agriculture & Land Use Change is Needed00:50:50 - The Case for Geoengineering via Sunlight Reflection & More00:54:50 - A Call to Action for Optimism & to Work on ClimateLearn more about Electric Era on their website: https://electriceratechnologies.com/ and follow Ramez Naan on Twitter: https://twitter.com/ramezIf you love listening to The Keep Cool Show, please leave me a 5-star review on Rate My Podcast: https://ratethispodcast.com/keepcoolThank you so much! Plus, stay up-to-date on all things Keep Cool here: https://keepcool.co/ and follow Nick on Twitter: https://twitter.com/nickvanosdol and LinkedIn: https://www.linkedin.com/in/nicholasvanosdol/
10.02.2024 11:30 am Saturday. Got the chance to talk and catch up with my first friend Ramez Azizi. We touched all topics good male friends touch: Career, politics, army, and life goals. And most importantly, waste management in large cities. A little bit of Arabic and English together. Youtube link: https://www.youtube.com/watch?v=MwdVC9wZIOY&t=2s
Brad Stone, Bloomberg News Senior Executive Editor for Global Tech, shares his AI insights from the World Economic Forum in Davos. Wedbush's Dan Ives details his takeaways from the CES conference. Dana Telsey of the Telsey Advisory Group discusses the strength of the US consumer in the wake of retail sales data. Charles Schwab's Liz Ann Sonders ties in Led Zepplein with her markets outlook. Hosted by Tom Keene and Damian Sassower. Get the Bloomberg Surveillance newsletter, delivered every weekday. Sign up now: https://www.bloomberg.com/account/newsletters/surveillance Full Transcript: This is the Bloomberg Surveillance Podcast. I'm Tom Keane, along with Jonathan Farrell and Lisa Abramowitz. Join us each day for insight from the best and economics, geopolitics, finance and investment. Subscribe to Bloomberg Surveillance on demand on Apple, Spotify and anywhere you get your podcasts, and always on Bloomberg dot Com, the Bloomberg Terminal, and the Bloomberg Business app. He is definitive on Amazon of course, the Trophy book right now Amazon Unbound. Jeff Bezos The Invention of a Global Empire. He joins us from Davos, the meetings of the World Economic Forum at brad Thrilled to have you with Bloomberg Surveillance this morning. Let me cut to the chase. I see AI at Microsoft is countable, revenue, co pilot, azore all the rest of it. And I see a lot of other AI is smoking mirrors. How do you parse between legitimate artificial intelligence future and the makeup, the fantasy, the comedy of it. How do you parse? Oh? Boy, well, thanks Tom for having me. Hi Damien. Look, I've been covering Silicon Valley long enough that I've seen this story play out before. We're at the beginning of a hype cycle. There will be disappointment a lot of you know, the visions of Agi computers that reason that change our world, they seem far fetched, you know. There there we talk about a trough of dissolutionment that will happen. But you're right that there you know that there are real revenues, real benefits. Yesterday, Microsoft announced that it was bringing its open AI powered co pilot to the office seat, so you know at twenty dollars a month, making it available small business as an individual users. That's real. Yeah, brtt I signed up last night. I was going to be reack. Can you see me, Damien? Can you see me do an artificial Intelli get out of the way. Fred. If I look at this, can you say that the Magnificent seven they seem to be away from the hype. How is the Magnificent seven going to create revenue and cash flow out of AI? Yeah? I mean they're the best position because they're they're they're selling the picks and shovels to all the miners. You know, this is Alphabet and Amazon and Microsoft running the world's most powerful cloud services and making basically AI available as a service to every university and startup in consumer goods company that you know wants to use these tools for a variety. It's it could be R and D could be customer service. So you know, even even though that'll be a work in progress there, the revenues will be real. My question for Santia Tom by the way yesterday was you know, do you control any of this. You're you're investors in open AI. You don't even have a board seat. You're like in the back of the bus with a seatbelt, and it's got such peculiar governance. And he said, you know, it's fine, we just want stability. So I don't know if I quite believe it. I think they're outsourcing a key competency. But they're in the cappards seat, the driver's seat because they did make that investment. I'm sure the Amazons and the Googles of the world wish that they hadn't passed up the open AI opportunity when they had the chance. Well, Brad, I appreciate you answering those two questions from that artificial personification of Tom Keen that wasn't really Tom Keen answering those questions, And my question for you is talk to me about deep fake videos X these platforms. What's to stop open AI and chat, GPT and all this artificial nonsense from mudding the waters ahead of the election? Yeah? Well, what it's funny because it is really the talk of the conference that you've got national elections in some seventy seven countries around the world. Half the world's population could head to the polls at the same time as this enormously powerful technology is made available to people, and what's to stop it from being missus? I know this is going to carry a lot of water with our listeners, but you know they are raising their right hand and putting their left hand over their hearts and saying, we're not going to allow our technology to be abusing. They really understand the risks. I mean, I mean do they? I think they do? They? I think they do because we've all seen this movie before and meta its reputation went through the meat grinder because social media was perverted. You know, yesterday, it's no surprise that Sam Altman's here. He spent time with us at the Bloomberg House, and before our interview, they posted a statement on their blog on their election policy and said that chat GPT cannot be used for any political campaign. And they said that images generated by DOLI, their their image maker, will carry a cryptographic watermark to show the providence. And but you know, and my question for Sam was like, these are great intentions. You've got the weight of all the black cat developers trying to break this stuff. How to enforce it where Meta and Google and TikTok have all kind of let failed it with the genie out of the bottle, right And he said, you know, they're aware of the risks. So I do think it's going to be a rocky year with some of these elections, and we're going to see this technology abuse, right, brand I'm sure that no one can forge those crypto water marks. I have one last question. I mean, my colleague Tim Craig had from BI is actually in Davos listening to Altman, and he said, I mean, you know, Paulman obviously spoke and he was talking about how AI will make people more productive. Talk to us a little bit about that narrative. The great worry is that when this technology is fully implemented, that there will be a great dislocation of workers at low level level programmers, customer service agents, you know, in en mass replacement along with productivity, and it will worsen the digital divide, and you'll have countries that are particularly hard hit, and it could lead to further political alienation and you know, maybe more or autocratic government's or real nightmare scenario. So you know, that's the worry. And I think the stewards of this technology, you know, Davos is the land of performative optimism, I kind of like to joke, And so of course they're saying that it's going to increase productivity and we're all going to lead better lives working less. You know, maybe Tom will get to sleep in one one morning when AI kind of takes over. But I don't know. I mean, you know, the I think it will make people more productive, but I think it might replace some jobs as well. More question, I think it's what everyone knows. With your your ownership of Amazon and all you've done with the Amazon unbound, They've gone round trip massive post pandemic collapse. The come back is the next Amazon, Josie's Amazon. Is it going to make total return like we've known over the last decade. Excuse me, so you're asking me about the stock price. I mean it's it's yeah. I mean, look, if I could predict it, I'd probably be in a different line of work. I mean, I do think. You know, Andy Jassey is now a couple of years into his tenure. He is and by the way he's here at Davos, he has pared back some of the excesses of the late stage Bezos that we just saw another round of Laos. This is becoming a very lead and efficient company as he bets on the core competencies, which is AWS and the Amazon marketplace, empowering third party sellers. They've got their work cut out for them. But I do think there's a bit of momentum there. Brad Stone from the meetings of the World Economic Forum, I can't say enough about his new book, Amazon and Bound. Jeff Bezos, The Invention of a Global Empire, Joining us now the Tech Pignata of two twenty four. Daniel Heize joins us in Webbush. He's been traveling ces Las Vegas, joining us today from Warsaw Poland. And what you learn at Las Vegas at cees don't give me the mumbo jumble. What was the backstory in Las Vegas? I thought it's about Ai just how mainstream the technology is getting. I mean, tom My opinion, the biggest cees in the last twenty five years. It shows this AI revolution it's not hype, it's real. It's on the doorstep. I want you to talk Dan Ives, and this is what you don't see folks, as Dan Ives is doing the media blah blah blah by this apple. The gloom crew hates them, but beneath it is careful financial work. Can you quantify what the new announcement of AI over to Microsoft three sixty five, like, can you add up the impact of that to a giant company like Microsoft. It's when you put it together, this is going to be eight hundred billion to a trillion of incremental value to the Microsoft story. I mean they are leading the AI revenlue with the Della and Redman, along with the godfather of AI jents and the video Tom I think the monzation that's happening in Microsoft is still so underappreciated in terms of what we're seeing in the field. Dan they're asking for more money, I mean they're asking for more computing power, more hardware, more technology. They say, this is not just big, it is massive. It is huge. Do you agree with that. I think it's the biggest transformational tech we've seen since Star of the Internet. And that's why enterprises they're lining up. Conversion could be sixty seventy percent. And that's why as Tom's talking about the doomsayers again, you know, obviously negative untech, I think this earning season turns that around because the real monization of AI is here. It starts from the Della and Microsoft and Dan. I mean the real I mean you just said it right there. Don't you need access to data, to unique data sets in order to basically make the AI go. And so when I think of Amazon, okay, find they've got access to consumer data, I think of Microsoft. It's everything else. You know, people on their computer and talk to us about these companies and the data they have access to and how that's going to differentiate them in the environment you're talking about. I mean, it's a new age. And that's why when you look at the cloud, the big hyperscale players, Microsoft, of course, Amazon, Google and others, they've had the data sets, but they haven't had the tools that they can monetize and make intelligence. That that's why the use cases are excluding. That's why this AI revolution right now, I believe it fuels is new tech bull market. I a February second, We're going to get Apple earnings. It's a ballet. I actually sit down with the beverage of my choice folks at the home computer after the surveillance n APP and what's a joy here? Is they release like other firms, a press release that's clear and in English? Dan ies, what are we going to see in the treatment of the four accounting statements from Apple? Four pm, February second. Yeah, look, that's the drum roll, right, And I think when Cooper Tino comes out, the big thing is going to be services. We are looking at team type of growth for services and that's key that could really be incrementally we need that as a one point five to one point six trillion services the margins double out of hardware obviously all focus on iPhone units. Despite obviously many yelling fire in a crowd theater, I actually think it was a pretty strong iPhone unit number. Okay, wait, well, want to get upside of the track now, Dan knows a drill, Damian pick it up here. Okay, But I'm sitting there with the beverage in my left hand, looking at the accounting statement, and the media is not readjusting the currency iPhone sales as mister Ive says, we're pretty darn good. And then you had to figure in dollar currency adjustments. Whoa doom and gloom? I mean, Ives is one hundred percent right about the iPhone of the global market, Tom. I mean, it just passed Samsung as the world's top phone in the full year twenty twenty three. But I mean, Dan, here's my question. What companies are best position to profit from what you're talking about here? I mean, is it the chip makers? I mean what sort of hardware companies? Is it software? I mean, what are you seeing? I think it's software and chips. When you look at names like Microsoft, the Magnificent seven, you can Microsoft, Google, Amazon. Then you look at some of these names like Mango, dB, Salesforce, dot Com and of course a MD with Lisa Sue and chips. This is the start of this tidal wave, A trillion dollars of incremental spend next decade. That's how this is all going to play out. Software and chips leading it. You know, I got one more for you. I mean, if you're a new company with you know, and you're in the AI boom, and you know you've got the talent, and you know you're competing. Where do you want to be located? Do you want to be on the West Coast? Do you still want to be in Palo Alto. I want to be based in a five one two area. Oh. Really, that's new look and that's what that's that's that's a silicon value two dot of you're seeing that boom more and more for AI engineers, and I think that's really started the new age that we're seeing from an AI perspective. Well, we'll help our international audience. What is Michael Dell and Venna down in Austin to the two of you, Damien? When you think five to one two South Congress, I think of South Congress. I think of barbecue. I mean I think of Austin, Texas. I mean that is the Los Angeles. I think of Joe Wisenthal's band myself. I think they're you know, outstanding dan Ees. What's special about Austin, Texas. I Mean, there's a lot of things special about Austin, Texas, but the engineering talent that that's been created there, obviously outside University of Texas, is really unprecedented. It's one of the you know, more and more tech companies from Google to of course Tessa to Meadow moving down there, and it's really becoming a really go to destination for tech leaving the four one five, going to the five one two worldwide on Bloomberg surveillance. And it's time now to make some news. You got a two hundred and fifty dollars price target on Apple. Can we lift that up to day? Miss Graves? I mean, look Tom, I mean you talk the bolt case. This will be a four trillion dollar mark ab we believe by the end of this year. I remember AI. There's zero dollars given for AI in Apple's valuation. That's why this is it. Get that popcorn ready in the key in household when they come out with that AI and au June from Warsaw poland a trooper to be with us in his travels. Dana is a Webush of course, outstanding work by him. It's he's with Webbush Security is optimistic on Apple and computers. Right now, we're going to talk about the pulse of the Christmas holiday this season that we saw. There's just no one better to do with this than Dana at Telsea with all of our heritage at the corner in Fifth Avenue in fifty seventh Street, her family's heritage, and she's done it in securities analysis per year at Dana, you were right, the gloom crew was wrong. What did the people of caution get wrong about retail America into the end of the year. I think overall, and Tom, thank you so much for having me. I think overall. One of the key things that was the difference is we had Christmas that was later this year, so people had more time in order to procrastinate, and so really everything was driven around the event days, whether it was the Black Friday weekend or then that week leading up to Christmas. It's what made the difference. It's not that holiday sales were so great, but goods sold at full price inventory levels only, and sales came in line with expectations for the most part. And as a Dana Telsea Microeconomics Damien sasaw or what she just said there goods sold at full price was to me my observation on it. You know, I'm curious, Dan, I'm curious to here we got some China date overnight, right, I know, I just I'm pivoting away here, but I mean, wow, that economy is sluggish, and I think a lot of the big luxury goods LVMH carrying her mad I mean, they were a pretty big overnight in Europe. Talk to us a little bit about what that GDP figure means to you, what it means to me, especially for luxury and I spoke last week to the CEOs of Neiman, Marcus and Sacks, and they all talked about the slowing and more challenging luxury goods environment. Look at Berbery's numbers, which we were just released at the end of the week last week, it talked about the slowdown and in Europe, the local slowdown spending and you're still not seeing the Chinese come over and spend, whether in Europe or in the US, anywhere near what we had pre pandemic. We're gonna get next week LVMH. And I think all eyes are going to be on what they say about the deceleration globally. Is there Tiffany experiment working out for those of you internationally? We have two blocks away from us, really across the street from where Dana grew up, Tiffany's with one hundred million dollars or so investment by the Arnoul family. Has that experiment been successful for LVMH. It has. Not only has it been successful, but also they garnered profitability much quicker, frankly than when it was a public company. And the way they've done it, they modernized the store, they've modernized the products. They've brought in influencers, celebrities that appeal to younger consumer. Think about it. You're talking about engagement jewelry. When do people get engaged twenties and thirties want to have a store to cater to that demographic. She's just joining us on Bloomberg surveinglist. Dana Telsey, the Telsey Advisory Group. She and Joe Feldman with great work across all of retail. And I know Damien Missus Sassa are called me up. She said, you got to ask about the ani there leathern Red Soul Christian labby Tom Boots one thousand and five hundred ninety five dollars. It's a way to get through the snow drifts. Yeah, no, I'm not in New York City. I'm not worried about demand with Missus Sasa right there. But what I will say and Dana, And this is my question for you. You know, El Nino, right, input costs, margins, you know, talk to me about the impact of El Nino on cotton prices on some of these things. I mean, do you see that kind of trickling through to the bottom line? It does? I mean one of the things keep in mind all the freight expenses and the tailwinds that companies got from lower freight costs in twenty twenty three. Apparel, it's going to benefit with lower cotton costs in twenty twenty four, but maybe not to the same magnitude. We're still going to need some level of sales leverage. And there are two drivers in twenty twenty four. It's about innovation and it's about value. You have those two elements and you'll have a formula to drive sales growth. So talk to us also. I mean on the input side, I mean, what are you thinking here? I mean, gas prices are now ticking up. Obviously we didn't see much evidence of that in the retail sales print. But you know, how does this really impact some of these you know, these large luxury goods companies. I mean, do you see any pack there? I don't for certainly for raw materials, cost increases, luxury goods. Companies have the power frankly of being able to raise price. You're certainly seeing Chanelle do it trying to reach what Ourmez is doing. But all the others you're not seeing price increases like you had, and they're managing their inventory much more carefully. I gotta go get your away from March data. Telsey, tell me about your single best buy when you and Joe Felman get to work. Where's the value? Is it in big box? Is it in middle of the road or is it in lux I think overall, definitely. I think when the weakness and luxury, like any weakness in LVMH, I think that's an opportunity. But really it continues to be about off price and discount. Given what you've seen in the moderation consumer spend a low TJX I mean air Mez, I mean, I guess leading Away is being least affected. Why are they trading at a multiple of forty seven times earnings? Because, frank when you think about something like Ramez, there is so far there is no level of supply where the demand doesn't exceed the supply. Miss yeah, perfect, I mean to interrupt Missus Sassar's on the phone. What's the question? She only shots at the Ponsovecchio in Florence. Tom Now, I mean, you know, I was just in Europe and I have to say, I mean there was a lot of foot track in some traffic in some of these places. And you know you talk about Hugo Boss, you know who had disappointing operating profits. I mean Berber you mentioned them. I think you know, the things seem to be turning around here in Europe. That's good to hear. I think that would help all a luxury. Lisa Mateo's here as well. She wants to ask the question. Lisa Matteo, question here for Dana Telsea to get your retail days started. Ooh, all right, what is the hottest? What should I be looking for? As far as you hear these talks about selling back those fashionable high end pocket books, if I just happened to have one at home, what's the remarket value of something like that? It depends if it's an ermez bag, whatever market value you walked it out of the store of or tried to bring it to someone to sell, it's higher. And for some I've heard it's at least ten percent higher. Even the day it walks out the door, it holds its value. What's the greatest brand destructure into Lisa Matteo's brilliant question, which is the bag Lisa wants to unload this morning? Do you want a higher price? A Birken or a Kelly? Is your bag that you're going to get a higher price? Dana Telsey, thank you. So it's give me a single best buy, please, I need a name here. Give me a single best bike. Go to TJX. Believe me, it's the winner for twenty four and they have the Kelly bag as well. Dana Telsey, thank you, thank you, thank you so much. On the real retail of America now joining us to piece it Together's liz Ane Saunders, chief investment strategist to Charles Schwab, She's in charge their led Zeppelin division or thrilled that you could join today. I look at the market and I need a whole lot of love here, and to me, the whole lot of love is going to come from six trillion dollars in money market funds. How much of that is going to go? At Schwab over to the equity market. I wouldn't necessarily count on a lot of it. I don't think that that should be seen as money that is poised to jump into the equity market. I think a lot of that is stickier money that might have been in other places, including traditional deposits, or in riskier places in order to pick up income that now can be in the safety. And also, yes, six trillion dollars is a record, but we're nowhere near a record as a share of total stock market capitalization. All you have to do is look to the nineteen nineties to see a period where you consistently saw increases in the amount of money and money market funds commensurate with the increase in the stock market, the drivers being different. So I don't view that as some sort of moment in time source of additional funds that would flow into equities. Right now, I'm confused because I get a stream of thought that people are cautious, nervous, and I get another stream of thought that everybody, including damiens ors O Pair, is in the market. Which is it at Schwab, is there an enthusiasm by your clients for equities? I think there's cautious optimism I wouldn't consider it over enthusiasm. In fact, if you look at attitudinal measures of investor sentiment more broadly than Josh Schwab, although at seven trillion dollars we're a pretty big slice of the retail investing universe. But if you look at attitudinal measures like AAII, those are purely attitudinal. It's survey base, and that's jumped around quite a bit, and it's just there tends to be more of a knee jerk reaction to what's going on in the market moment in time. But even within that survey you get the equity exposure, and at times where you've seen bearishness really pick up fairly quickly, it's not met with a similar move down in equity exposure. So I think when looking at sentiment, you've got to look at the marriage between the attitudinal side and the behavioral side. Interesting and of course, in the nine o'clock are here Wall Street time, Damien Sassar has been medicated to tang mimosas have clicked in Damien. No questions to lizan on Indonesia. Okay, I'm not going to channel Robert Planting led Zippelin led Zeppelin now Lizan, but I am going to channel Pink Floyd. I'm gonna channel Roger Waters. Here are the markets comfortably numb to the concept of a FED cut in March? I mean, let's be clear, I mean like, this is unbelievable that you know the markets are priced that way, yet you know it seems to becoming fast becoming consensus. What are your thoughts on that? So we have seen a bit of a shift, particularly with with today's retail sales report. So a week ago, if you look at probabilities in terms of FOED funds future market of what's going to happen at the March FOMC meeting, you were up at around sixty five percent probability. I think that's down to I don't know, fifty seven or fifty eight percent now, and it's been kind of a moving target. So I think the market may slowly be adjusting to what. Frankly, most FED speakers have been trying. The message they've been trying to impart is you know whoa all l squel. It's given what we know now, it is probably not a backdrop supportive of not just starting as soon as March, but the FED providing you know, six rate cuts this year. I think that disconnect still exists, it's just not as wide as it was even a week ago. So then lusanna backuping yields means, I guess from the equity perspective, you want to get a little bit more defensive. What areas of the market would you go to to protect to protect in this type of environment. I mean you would think classic defensive sectors like you know, utilities. I mean, I mean, look at where valuations are there, I mean, what works in your portfolio. Well, so there are the classic defensive sectors like utilities. Then there's this era's defense sectors, which incorporates what I call the growth trio of tech communication service as a consumer discretionary of course, housing all of the Magnificent seven and really all the way back to the early part of the pandemic. That's been this era's defensive type names. And that's because of strength the balance sheet. They don't have to rely on funding in the traditional banking system or even in the capital markets. So defensive is just a descriptor. It's not some well determined type, and it is quality and you know, it's specific to the beginning of your question with this direct relationship in yields, I mean the peak and yields. It gave us the big move up from late July, I mean from late October until the end of the year. But then we saw that bottom end yields, and that meant we saw the market rollover, particularly small caps. And one of the things we've been saying, especially with small caps, do you know there's money that's once to find ideas down the cap spectrum, but do not sacrifice quality, particularly when you go down the cap spectrum. So you want to still have that strength of balance sheet, interest coverage very importantly, especially as yields tick back up again, strong return on equity, have an actual earnings profile, don't be a zombie company or a non profitable company. And I think that's a lesson being taught in the last few weeks. Well, Lazan, I do have one last question there, what about this low volatility factor. I see a lot of investors moving into low VALL as sort of a defensive way of approaching the equity market. Here, how did those sectors screen from a low VALL perspective? So it's a factor that has done well when the other quality factors have been doing well, when you get these moves shifts in expectations for either FED policy or the economy, and you see it reflect and yields. You can go through short periods where you get higher volatility, higher variability as factors that do well. I think those you probably want to fade those lower quality factors, And I think low volatility maybe not as important as it was last twoar but I still think it's in the basket of quality oriented factors. Lisanzi, your iconic work. How for our listeners are viewers on YouTube? How do you avoid a Boeing? How do you avoid a Disney? How do you avoid blue chip stocks that blow up? Well, don't have a heck of a lot of your portfolio invest in any one name or even group of names. So I think that that's one of the messages that come from things like the mag seven. There's nothing wrong. There's a reason why those stocks have done well because they check the boxes on so many of those quality factors. But be mindful of volatility and portfolio based rebalancing. You know a lot of investors do the rebalancing based on the calendar. They might do it once a year, at best once a quarter. But our message has been let your portfolio tell you when it's time to rebalance, even at the individual stock level, where the moves in your portfolio are going to dictate when you add low and trim high. Maybe don't focus so much on doing it at the calendar. Okay, trigger, stop the show. This is the single most important insight of the day for all of you listening and watching. I can't say enough the importance of moving to a Sander's percentage ownership rebail versus a calendar gimmick invented by marketing people that have never owned a share of Anaconda Copper in their life. Liz Anna, what percentage is a vanilla statement? Do you rebail? Is it when something gets the five percent of portfolio? Or is there a Sander's magic number. I don't know that there's a magic number for individual investors. Keeping mind though, that part of the issue with the mag seven and how big they've become as a share of the SMP recently hitting thirty percent, is that even institutional managers, whether it's mutual funds or even ETFs, have perhaps on how much they can own if the S and P. If someone just said, hey, let's create this index and here's what's going to look like. It wouldn't actually pass muster or securities regulations, not to mention the fact that many fund managers can't hold such a large share of those names. So you can use that as maybe not an exact guide for what percent becomes too much, but this notion that there are going to be a lot of institutions that simply have to trim because of their own guidelines on how much they can own of the stock. Just in many cases it's fibers. We've got to interrupt with. And just in from led Zeppelin News, Robert Plant will tour the United Kingdom with Saving Grace. Look for that two thousand and twenty four. I want to see him tour with Jimmy Page and John Paul Jones and Jason Bottoms. So that's what I'm waiting for. That's what she's waiting for, and she will be there in the arena when they do that. So well, Lizzie Siders, thank you so much. Subscribe to the Bloomberg Surveillance podcast on Apple, Spotify and anywhere else you get your podcasts. Listen live every weekday starting at seven am Eastern. I'm Bloomberg dot com the iHeartRadio app tune In, and the Bloomberg Business App. You can watch us live on Bloomberg Television and always I'm the Bloomberg Terminal. Thanks for listening. I'm Tom Keen, and this is BloombergSee omnystudio.com/listener for privacy information.
In this "Podcast Takeover," Dr. Lidia Schapira guest hosts to discuss with Dr. Shannon Westin her own JCO paper, which reports on the DUO-E Trial. Dr. Ramez Eskander also joins in this lively discussion. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts published in the Journal of Clinical Oncology. I am your host, Shannon Westin, Social Media Editor of the JCO and Gynecologic Oncologist by trade. And actually, I'm super excited today because we are going to have a podcast takeover because we are discussing my own work, which was simultaneously presented at the European Society of Medical Oncology 2023 Congress and published in the Journal of Clinical Oncology on October 21st, 2023. And this was the DUO-E trial, “Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer.” Because we're discussing this work and we wanted you to have an unbiased podcast discussion, Dr. Lidia Schapira, who is a Professor of Medical Oncology at Stanford University and an Associate Editor of JCO and the Art of Oncology podcast host, is going to take over this podcast and really just pepper me with questions about this exciting work. Welcome, Dr. Schapira. Dr. Lidia Schapira: Thank you so much. It's such a pleasure to be with you. Dr. Shannon Westin: And before I turn over the reins, I also want to introduce one of my colleagues, who's going to be providing quite a bit of insight on this topic, Dr. Ramez Eskander, who is Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Diego. And you will know he's the principal investigator of the GY-018 study, which established pembrolizumab and chemotherapy as the new standard of care in endometrial cancer. Welcome, Ramez. Dr. Ramez Eskander: Thank you. Thank you, Dr. Westin. It's a pleasure to be here. And congratulations again to you and your study team for this exceptional work. Dr. Shannon Westin: Thank you. And congratulations to you. Dr. Schapira, thank you for being here and please do take it away. Dr. Lidia Schapira: So let's start by having you tell us a little bit about the standard of care for women with endometrial cancer and advanced endometrial cancer prior to this study. Ramez, I'm going to direct this question to you first. Dr. Ramez Eskander: For many years, actually since about 2012, carboplatin and paclitaxel, which ironically is a chemotherapy backbone really across all of our gynecologic tumors, emerged as the preferred doublet chemotherapy regimen for the management of advanced-stage metastatic or recurrent endometrial cancer. It evolved through a series of different clinical trials, in fact taking us from whole abdominal radiation, systemic chemotherapy, comparing single agents to doublets and then triplet regimen of TAP to carboplatin and paclitaxel, which ultimately, then, following the presentation of GOG Protocol 209 and its publication, as the chemotherapy backbone, being carboplatin and paclitaxel. And it's been that way for many, many years. Dr. Lidia Schapira: And how effective is the regimen? Dr. Ramez Eskander: The response rates to carboplatin and paclitaxel are actually quite reasonable in the patients who have advanced-stage disease, particularly if they haven't had prior systemic chemotherapy. Response rates in the 50% to 60% range. The issue is that the responses tend to be limited and disease recurrence is an expectation in these patients who have advanced-stage disease. And so that really highlighted the importance of trying to continue to advance therapeutic opportunities in these patients to improve long-term outcomes. Dr. Lidia Schapira: As we think about improved long-term outcomes, we're thinking about a better treatment and also a kinder treatment, perhaps one that is also less toxic. Can you talk a little bit about the population of women with endometrial cancer? Are these older women? Do they have comorbidities? Dr. Ramez Eskander: What we're seeing is, interestingly, there has been an evolution a bit in this space. Historically, we used to think about endometrial cancer as—the phrases we used to use are type I and type II. These type I tumors, we would say, are estrogen-driven malignancies; they tend to be seen in overweight or obese patients. And we would identify them in a theoretically younger patient population. And then we had these type II, or what we termed estrogen-independent malignancies, that we would see in an older patient population. Of course, with obesity came metabolic syndrome and other cardiovascular comorbidities, etc. But really, that narrative has evolved dramatically, and that's really something that will be highlighted in, I think, our discussion of these studies today, where the nomenclature that we used to historically use has evolved because of our understanding of the molecular characterization of this disease. So we've really gone away from that, and now we understand that we're seeing all of these different heterogeneous endometrial cancer types amongst patients of different ages, different comorbidities, different races and ethnicities. And so it's created a more complex picture for us. But certainly, there are comorbidities that these patients face, and that's important as we look to identify treatments strategies that are both effective and tolerable. Dr. Lidia Schapira: My final question before we jump into this very exciting study is about the Cancer Genome Atlas work. Can you tell us how that's changed the thinking and the design of the studies? Dr. Ramez Eskander: It was a seminal publication, really, back in 2012/2013 looking at an assessment of endometrial cancers to try and determine whether or not all of these "endometrial cancers" that we used to enroll on a single study are similar or divergent. And it's important because the study I referenced that really established the standard of care, GOG Protocol 209, as carboplatin and paclitaxel, there was no real consideration of molecular characterization at all. We enrolled all patients onto this study without thinking about these variables, of course, because it was designed, conducted, and completed before the TCGA data emerged. But what we learned from the TCGA is there appeared to be four distinct molecular subgroups. There were the POLE-mutated patient population. There was the mismatch repair deficient or MSI-high endometrial cancer population. There was the copy number-high or what we say are the p53-mutated. And then the last cohort was called the NSMP (no specific molecular profile). But now, that's even evolved; some people term it TP53 wild type. That's a bit of even a heterogeneous cohort amongst itself. So we're going to take these subsets, independent of POLE and an MSI-high, and we're going to look at TP53 or copy number-high, and that will probably be divvied out further, and the NSMP, and that will probably be subdivided. But really, it gave us these four components, which has then evolved. Many of you may have heard of the ProMisE algorithm or ProMisE Plus, which looked to take the data from TCGA so that we can start to really look at it in clinical practice. So it's really revolutionized how we think about these patients, how we think about the disease, and how we design trials. Dr. Shannon Westin: And I just want to add to that because I think that it's so important, what Ramez said about the way we were developing trials, the way we were designing trials. We knew that these classifiers—we were learning these classifiers are prognostic. Now what we're really trying to hone in on is how predictive they are. And certainly, one of the major classifiers that we're going to talking about today is mismatch repair status, and that is most definitely predictive of response to therapies. But we're still learning about the other classifiers and how we might adjust the way we treat people, even deescalating care for certain patients. That is still being proven in clinical trials, although we suspect that it's going to be borne out as other clinical trials report. Dr. Lidia Schapira: It's a perfect segue to this current trial. Tell us a little bit about the objectives and the design of DUO-E. Dr. Shannon Westin: As Ramez said, the standard of care was chemotherapy. And so we wanted to see if there was a way to improve outcomes for these women with advanced and recurrent endometrial cancer in a really clinically relevant, meaningful fashion for patients. And so we knew that this TCGA classifier, the mismatch repair, was so important, and we thought that the addition of immunotherapy to chemotherapy would most certainly work in that population but could even work in the entire population because, generally, endometrial cancer seems to be a little bit more responsive to immunotherapy and to activation of the immune system than, say, some of our other gynecologic malignancies. And so we set out to see what the addition of durvalumab, which is a PDL-1 inhibitor, would add to chemotherapy. And this was two chemo as well as followed by durvalumab maintenance. But even further, we had some really kind of exciting science data from our lab that said that if we combined a PARP inhibitor with immunotherapy that we could accentuate on the response to therapy and we could get more benefit. And there's kind of a lot behind that, but essentially, what we thought was that the damage that's caused by the PARP inhibitors would create an activation of different immuno-pathways, like STING pathway and activating cytokine release, and that we would get this synergistic activity. So one of the other objectives was to see if the addition of the olaparib, the PARP inhibitor, to durvalumab in that maintenance setting could even further improve benefit. So we had a dual primary endpoint looking at progression-free survival, so the amount of time people live without their cancer coming back. And that endpoint was first, the durvalumab-alone arm to control, and then the second portion of that was the durvalumab/olaparib arm back to control. Dr. Lidia Schapira: So before you tell us about the results, tell us a little bit about the study itself. I mean, I was very impressed that you did it in so many different locations. Tell us about that effort. Dr. Shannon Westin: This was a huge collaborative effort both with the GOG Foundation, the Gynecologic Oncology Group Foundation, as well as ENGOT, which is our European colleagues that do amazing clinical trials. But in addition to that, we really worked very closely with our industry partner to really make sure we spanned the globe. And so we had groups from all over the world that participated and really were exceptional. The care that was taken and the hard work that went into this type of study across the world really can't be overstated. We were very lucky to have a wonderful infrastructure group. We met weekly for a long time, just keeping an eye on the data and making sure that everything was as positive as possible and, of course, that we were watching the outcomes of the patients very closely and making sure that there was no evidence of harm or issue. And so it really did take a village, truly, to run this study and to ensure that at the end of it, we got really great data that we can trust. Dr. Lidia Schapira: So tell us the results. Dr. Shannon Westin: So DUO-E was positive for both of its primary endpoints, which was very thrilling. So for the first analysis, which is the durva-alone arm to control, we saw a reduction in the risk of progression of 29%, so a hazard ratio of 0.71. And then the addition of olaparib seemed to further enhance this benefit, so a 45% reduction in the risk of progression for a hazard ratio of 0.55. But what's really exciting is our follow-up time was pretty long; it was about 17 months, so we were able to look at a couple of different analyses, including an 18-month landmark analysis where we saw approximately 50% of the patients were still alive progression free at 18 months, as compared to only 21% of patients being alive progression free in the control arm. So there was a doubling in that progression-free survival time point at 18 months, which is thrilling. Dr. Lidia Schapira: So Ramez, as an expert in the field, what was your reaction when you read or heard these results? Dr. Ramez Eskander: It's exciting, honestly. So we have gone a long time without seeing really significant successes in the endometrial cancer space, a testament to the fact that we hadn't yet developed our understanding of how we could move this needle forward. But Dr. Westin and the DUO-E team conducted an exceptional clinical trial, as you mentioned, international study, rational and important hypothesis to adjudicate. And what we saw here was both now we had other studies—the RUBY trial, the GY018 trial, the AtTEnd—and now here DUO-E, which added this hypothesis of PARP maintenance in addition to checkpoint to try to augment response and consistent, really provocative data, exciting, in line with what we've seen and hopefully will continue to drive the science in this space, most importantly. Dr. Lidia Schapira: So let me ask you a follow-up question to that. What kind of scientific questions are in the air now as a result of this trial and what the trial found? Dr. Ramez Eskander: Oh, goodness. Shannon and I could both take this, I'm sure. But I think in the dMMR population, we recognize that there's a ton of data that is supportive of the fact that these tumors are immune responsive, particularly in dMMR endometrial cancer, whether it's an epigenetic promoter hypermethylation, or a mismatch repair gene mutation. I think the data has emerged that immunotherapy is here to stay for these patients in the newly diagnosed advanced stage, even chemo naïve, who need adjuvant therapy. The pMMR population, this is where we're seeing more and more questions emerge because we realize that that may be a cohort of different cancers. And I'll let Shannon speak to this briefly, but even the incorporation of the PARP inhibitor, in addition to the checkpoint, there's a biologic rationale for combining those two together to augment response. And to see the benefit in that trial—arm three and arm two, we can look at descriptively and look at the differences, but who are those patients? Where is the PARP and the checkpoint most effective? How do we expand that to a larger population of patients potentially? These are questions that emerged because, as Dr. Weston will allude to, I know we also talk about HRR mutations, which are captured, but we even have a lot to understand about that in endometrial cancer, where we've had more research in the ovarian cancer space. Dr. Shannon Westin: Being mindful of time, because I have, like, 1,000 hypotheses that have been generated by this study, which, I think, shows it's a great study, right? Because you get some answers, and as our colleague Brad Monk says, “The only definitive study is the negative studies.” This most certainly was not that. But just kind of expanding on what Ramez said, the interesting thing about DUO-E is that really the biggest benefit for the combination of the durvalumab and olaparib was in that mismatch repair proficient group. And I personally thought that we were going to see accentuation of the impact in the mismatch repair deficient group based on the science, but that just wasn't borne out by the data. It doesn't seem that the combination has that much to add in that mismatch repair deficient group. And when we tease out the mismatch repair proficient group, I think that's where a lot of interesting information is going to come because, to Ramez's point, we're going to tease out: Is it driven by the P53-mutant population? Is it driven by the population that has homologous recombination deficiency? How do we even measure homologous recombination deficiency in endometrial cancer? So I'm super excited about what we found and how that may help us to make those decisions for the patient in front of us. The other thing I think needs to be made mention of—and this was something we saw in DUO-E as well as AtTEnd—we had a large population of patients that were recruited in Asia, 30%. Interestingly, when we look at the forest plot, that group doesn't seem to benefit as much from the addition of the olaparib. So we really need to tease out what's different about that population because what Nicoletta Colombo presented around AtTEnd, it looked like they didn't benefit from the atezolizumab either in that study. So there's clearly something different about that population, and we have a really big opportunity to look at that since we had such a large proportion of patients that were enrolled there. So that's another, I think, really intriguing question. Dr. Lidia Schapira: So how does this fit in the context of endometrial cancer treatment, and what are we going to do with patients in the clinic? I'd love to hear both of your perspectives, starting with you, Ramez. Dr. Ramez Eskander: It's an evolving answer, to say the least. What we can say definitively is that we have a United States FDA approval for the regimen of dostarlimab plus carboplatin and paclitaxel in the mismatch repair deficient, advanced-stage/recurrent or metastatic patient cohort. And again, that's because the magnitude of benefit that we saw in the RUBY trial, which looked at that, was actually analogous to what we saw in 018, AtTEnd, and DUO-E, again, consistently highlighting the benefit of the IO and the dMMR. We have yet to see how this is going to evolve the landscape in the larger patient population, which is the pMMR patient population. And it may be that based on the data that we have, we will see immunotherapy plus carboplatin and paclitaxel as the new standard of care in the pMMR cohort, or it may not. That's yet to be defined. And I think Dr. Westin will add to this, but I think that's also going to depend on the perception of how we view the cohort. Is it one group of patients? Are we going to have to think about subsets within the pMMR population? That is an active conversation. Dr. Shannon Westin: I would just add, having treated patients on this combo regimen with the durvalumab and olaparib, I have multiple patients that still remain on study, and this—we're looking at three and four years out. I just never saw anything like that before with standard chemotherapy, so there's definitely something here. So I want to know who those patients are, who benefits really the best from the combination, and who could we just give the immunotherapy to and get that same benefit. So we obviously always want people to live as long as possible. That's the bottom line. But we don't want to overtreat. And so I think balancing that is really important. Dr. Ramez Eskander: The point that was made earlier: We have yet, aside from MMR response to checkpoint, within the pMMR population, we understand that there may be subsets, but we have yet to prospectively validate that these molecular cohorts within the pMMR population are truly defining response to a particular therapeutic strategy. So we have to be cautious not to limit the treatment opportunities for these patients without having the data that we need to do so because, as Dr. Westin mentioned, for us—whether it was the Gy018 trial, the RUBY, the DUO-E trial—what we saw is there are pMMR patients who have a dramatic response even though they are “biomarker negative.” They're pMMR, they're TMB low, they're not POLE mutated, but yet they still derive a dramatic benefit. And so that goes back to the hypothesis about why we're even combining checkpoint with chemotherapy in which, for example, in lung cancer, there's been established success and approval. So I think we're all eager to see these strategies emerge as treatment opportunities for the pMMR patients as we work to still develop additional effective opportunities. Dr. Lidia Schapira: So, based on all of this and sort of the new twists on the scientific hypotheses that are now generated, what are the next steps? Dr. Shannon Westin: Well, I think we have to see if these drugs are available for patients. So looking at things like compendium listing and regulatory approvals obviously is going to be very important. But from the things that I can control, we are looking at the different molecular subtypes and understanding the different mutation status and trying to tease out who may be driving the biggest benefits so that we can help advise and make sure that we're doing the right thing for the patients. Dr. Lidia Schapira: And wearing my supportive care hat, I have to ask you, Shannon, about the tolerability. We often find that the quality of life and studies come out after, sometimes months or years after, the original trials are published. So let me take this opportunity to ask you now: How did women tolerate these drugs? Dr. Shannon Westin: The bottom line, Lidia, is, as expected, when you add additional drugs, you see additional side-effects. I think the good thing is that we're very comfortable with immunotherapy and we're very comfortable with PARP inhibition in gynecology because we have had access to these agents and so we know how to manage the toxicities. And so, from a standpoint of incidence, there was a higher incidence of grade three and higher adverse events in the group that had durvalumab/olaparib. But this was primarily driven by anemia, which is as expected and is usually pretty time-limited at the start of olaparib. From a long-term standpoint, there was a slightly higher proportion of patients that discontinued therapy, but it actually wasn't as much as I was worried about. So we saw a 19% discontinuation rate in the group that was just the control arm, and that went up to 24% in the dual arm, so definitely higher, but not that much higher. And when we moved to maintenance, which is really where—that's where the arm becomes unique, it was much lower at about 12%. And so that's exciting to me, that patients were able to stay on a drug and were able to tolerate it. And then, to your other point, we do have a very nice patient-reported outcomes plan, and that is actually being analyzed as we speak with the hope of presenting it at the next major meeting, our Society of GYN Oncology meeting in March. So not right away, but I think in a pretty timely fashion, we'll have those data. Dr. Lidia Schapira: Congratulations, Shannon, on leading and presenting this wonderful study. So it's been a real pleasure to chat with the two of you. Dr. Ramez Eskander: Thank you. Dr. Shannon Westin: Thanks so much, Lidia. I really appreciate it. Thanks, Ramez, for being here. And I will just say thank you to all of our listeners. We really hope you enjoyed this episode of JCO After Hours, where we discussed the DUO-E trial, which is a phase III trial evaluating durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer. And again, please do enjoy this publication that was online at the Journal of Clinical Oncology on October 21st, 2023. And do check out our other podcast offerings wherever you get your podcasts. Have a wonderful day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
In this episode, we interview Doug Birdsall (former CEO of the Lausanne Movement) and Ramez Atallah (former Vice-Chairman of the Lausanne Movement). They share personal encounters with iconic figures such as Billy Graham, Thomas Zimmerman, and John Stott, while also unpacking the rich legacy of the Lausanne Movement. Together, they delve into the challenges faced by global missions today, share stories of unity among mission organizations, offer words of encouragement for younger leaders, and discuss their hopes for the landmark Lausanne Congress in Seoul 2024. Subscribe to our podcast for more inspiring conversations that aim to accelerate global mission. For further information about the Lausanne Movement, please visit our webpage: https://www.lausanne.org.
SceneNoise and Sandbox Festival teamed up to bring the Selectbox experience to the beaches of Egypt's El Gouna Red Sea. Over three days our little box of noise gained a cult-like following as a hidden escape for a cosy dance whilst discovering some hidden gems of the regional music scene on the line up. Sandbox Festival is an annual electronic music festival that takes place on Egypt's Red Sea featuring a line-up of local and international selectors across three days and multiple stages. www.scenenoise.com www.sandboxfestival.com
ضيفنا حلقتنا الجديدة من البودكاست هو: رامز ماهر، رائد أعمال مصري بيشتغل في مجال تنمية المجتمع وريادة الأعمال، وهو مؤسس مؤسسة حلم، وهي منظمة غير ربحية بتهدف لدعم الشباب ذوي الهمم وتمكينهم في المجتمع، من خلال توفير فرص التعليم والتدريب المناسبة لهم، رامز بدأ رحلته دي من أكثر من 10 سنوات، وعنده خبرة كبيرة في مجال العمل المجتمعي، هنتعرف سوا أكتر على رامز وخبراته الكبيرة دي، في حلقة النهاردة، تابعونا.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ramez N. Eskander to discuss NRG-018 pembrolizumab and chemotherapy in uterine cancer. Dr. Eskander is a gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, including minimally invasive (robotic) surgery, chemotherapy and novel drugs. Highlights: NRG-GY018 showed that the addition of pembrolizumab to chemotherapy, followed by maintenance pembrolizumab, resulted in a 70% lower risk of disease progression or death in patients in the dMMR cohort and a 46% lower risk in the pMMR cohort than in the placebo group. These data suggest that the incorporation of immunotherapy into the first-line treatment of advanced or recurrent endometrial cancer improves oncologic outcomes, regardless of MMR status or histologic findings. Previous monotherapy drugs against PD-1 and PD-L1 in recurrent or metastatic pMMR endometrial cancer resulted in only modest improvement.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ramez N. Eskander to discuss NRG-018 pembrolizumab and chemotherapy in uterine cancer. Dr. Eskander is a gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, including minimally invasive (robotic) surgery, chemotherapy and novel drugs. Highlights: • NRG-GY018 showed that the addition of pembrolizumab to chemotherapy, followed by maintenance pembrolizumab, resulted in a 70% lower risk of disease progression or death in patients in the dMMR cohort and a 46% lower risk in the pMMR cohort than in the placebo group. • These data suggest that the incorporation of immunotherapy into the first-line treatment of advanced or recurrent endometrial cancer improves oncologic outcomes, regardless of MMR status or histologic findings. • Previous monotherapy drugs against PD-1 and PD-L1 in recurrent or metastatic pMMR endometrial cancer resulted in only modest improvement.
Metaphorosis magazine - beautifully written science fiction and fantasy
Along with the rest of humanity, Laila is struggling to survive Earth's Nuclear Winter, when her boss hands her an assignment she can't refuse. To help the Angels, and keep the job she desperately needs, she has to swallow her many resentments and grievances and set out on a journey through humanity's writhing underbelly. Along the way she is forced to reassess her views of Earth's overlords, humanity's destiny, and ultimately her own. Narrated by host Matt Gomez. Published in Metaphorosis on 05 May 2023. Find the original at magazine.metaphorosis.com.
In this episode I interview Ramez Shamieh. Ramez has always been full of energy his entire life. Over the years, he has learned how to channel this energy into creating a life full of abundance for his family and everybody in his path. He practices opening his heart daily and attributes the following practices to his growth: active listening, yoga, foundation training, meditation, and Breath work. One of his recent new passions is guiding breath work all across the country. He DJ's on special occasions and loves connecting people. He built a successful law firm from the ground up and he attributes his success to his incredibly talented team. He currently resides in Dallas, Texas with his beautiful wife, Anissa, two year old son, Zealand and his doggy dog Zizeaux. Check out his Instagram @ra_musiqaa at https://instagram.com/ra_musiqaa?igshid=YmMyMTA2M2Y= Check out his Shamieh Law firm instagram at https://instagram.com/shamiehlaw?igshid=YmMyMTA2M2Y= Connect with me on Instagram @dradrianmehmedi and let me know what you think of the episode!https://www.instagram.com/dradrianmehmedi/Subscribe to Healing Intentions:Apple: https://podcasts.apple.com/us/podcast/healing-intentions/id1513511677YouTube: https://www.youtube.com/channel/UCvCVBWBzJlgijJyHGJZ_ZiwSpotify: https://open.spotify.com/show/0Br46boiZpBXbdbgLxhk0UGoogle: https://podcasts.google.com/?feed=aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS8xMDgxNDMwLnJzcw==
Main Fiction: "Rockhoppers" by Ramez YoakeimA one-time engineer and educator, Ramez Yoakeim's work favors the darker side of speculative fiction but mostly he writes about hope, including "More Than Trinkets," named one of Tor.com's Must-Read Speculative Short Fiction. You'll find more of his stories in Hidden Realms from Flame Tree Press, Sci Phi Journal, Translunar Travelers Lounge, Andromeda Spaceways, and many others. Discover more on his website, yoakeim.com, and Twitter @RamezYoakeim.This story is original to StarShipSofa.Narrated by: Christina M. RauChristina M. Rau is the author of the 2021 poetry collection What We Do To Make Us Whole (Alien Buddha Press), the Elgin Award winning sci-fi fem poetry collection Liberating The Astronauts (Aqueduct Press) and the chapbooks WakeBreatheMove (Finishing Line Press) and For The Girls, I (dancing girl press). She is currently serving as Poet In Residence for Cedaremere, Poet In Residence for Oceanside Library and was named Long Island Poet of the Year 2020 by Walt Whitman Birthplace Association . She is also the founder of Poets In Nassau, a reading circuit on Long Island, NY. She teaches English at Nassau Community College where she also serves as Editor for The Nassau Review.She earned her MFA in Creative Writing at LIU Southampton, her MA in English and Creative Writing at Hofstra, and her BS in English at SUNY Oneonta.Fact: Looking Back At Genre History by Amy H SturgisSupport this show http://supporter.acast.com/starshipsofa. Hosted on Acast. See acast.com/privacy for more information.
Ramez Eedo arrived in Wagga Wagga with his family in 2019. Since their arrival they wanted to open a restaurant as the family has experience in this field. They owned a restaurant in the Kurdistan Region. But, they faced many difficulties in order to open their restaurant in Wagga. Kebab Erbil opened on January 13 2023. The family hopes to open more branches in other cities in Australia. - Ramez Îdo bi malbata xwe re di sala 2019an de gihîşt bajarokê Wagga Wagga. Ji dema hatina wan ve wan dixwest xwaringehekê vekin ji ber ku malbat di vî warî de xwedî ezmûn e. Li Herêma Kurdistanê ew xwediyê xwaringehekê bûn. Ji bo vekirina xwaringehekê li Australya ew rastî gelek zehmetiyan bûn, ne wek Herêma Kurdistanê ku hêsantir e. Kebab Erbîl di 13/01/2023 de li Wagga Wagga hat vekirin. Malbat hêvî dike ku şaxên din li bajarên din yên Australya vekin.
Business Unveiled: Expert Tips and Secrets from Top Creative Industry Professionals
Recently I had the most amazing experience in Egypt, and my friend Ramez Salama, co-founder of High End Journeys, is sitting down with me to talk about all things luxury travel and exclusive luxury experiences. High End Journeys is a boutique luxury travel agency, started by Egyptologists and best friends, Ahmed Aziz and Ramez Salama. Both share a passion for travel and draw on their combined industry experience of 34 years to deliver a personalized itinerary for their guests. They work with a singular aim in mind - to create unforgettable memories for every traveler. We touch on how to step out of your comfort zone and stand out to create experiences that no one else can offer. Details are everything, even the smallest details can make the biggest impact. Main Topics: *Your comfort zone is not your comfort zone*How to stand out and create experiences that your company can offer exclusively*Details are everything, even the smallest of details can make the biggest impact Key Takeaways: *Step out and see what happens, removing yourself from the comfort zone may change your life for the better*Curate a team that wants to grow with you*No one knows your country or experience better than you More About Our Guest: High End Journeys is our vision for what a high-end luxury tour should be all about: connecting people to people; helping people experience Egypt outside the tourist bubble; allowing Egypt to inspire and change our understanding of the world around us all. Egypt's ancient history and timeless culture have the power to transform the lives of our guests. We have witnessed that incredible transformation first hand and know that we are called to accompany this next generation of travelers to Egypt to continue to be changed by its people and its treasures. Ramez Salama's love and passion for his country and its amazing history led him to study Egyptology from Helwan University. He has guided a selection of leading diplomats, foreign businessmen, and world-famous musicians. He loves meeting people from different countries and explore their cultures. He has traveled to over fifteen countries - from the Great Wall of China to the game parks of Eastern Africa. He has seen the great castles of Europe, and hiked across the outstanding nature trails of North America. Ramez delivers lectures on Egyptian history and heritage at American churches and schools – particularly in Kansas, Texas, and California. He also serves as a guest lecturer on Windstar Cruise Line. Ramez's area of expertise is Pharaonic Egypt, and he takes pleasure in leading clients around the Great Pyramids of Giza.
Case-based workup and management of Rectal Cancer. Featuring guest Dr Ramez Kouzy.
Rent To Retirement: Building Financial Independence Through Turnkey Real Estate Investing
You've heard the term “self-direct” when it comes to 401ks and IRAs. What that means, however, and how you take advantage of it, isn't something that's usually defined. Zach Lemaster and Adam Schroeder talk with the IRA Club's Ramez Fakhoury to discuss how you can actually convert your retirement accounts into controllable assets and what investing with them actually looks like. Learn more about Ramez and the IRA Club HERE Use the code 'RTR' to get a FREE IRA account for your first year -------------------------------------------------------- Website - www.RentToRetirement.com YouTube - www.YouTube.com/RentToRetirement Current Hotlist Properties - www.RentToRetirement.com/Hotlist
Rent To Retirement: Building Financial Independence Through Turnkey Real Estate Investing
You've heard the term “self-direct” when it comes to 401ks and IRAs. What that means, however, and how you take advantage of it, isn't something that's usually defined. Zach Lemaster and Adam Schroeder talk with the IRA Club's Ramez Fakhoury to discuss how you can actually convert your retirement accounts into controllable assets and what investing with them actually looks like. Learn more about Ramez and the IRA Club HERE Use the code 'RTR' to get a FREE IRA account for your first year -------------------------------------------------------- Website - www.RentToRetirement.com YouTube - www.YouTube.com/RentToRetirement Current Hotlist Properties - www.RentToRetirement.com/Hotlist
As Second Commissioner and CIO, Ramez Katf provides leadership and strategic direction on information and communications technology in the ATO and ensures the delivery of technology services to support staff. He also ensures that the organisation is leveraging the most innovative trends in technology, to improve the experience of staff and clients. Before joining the ATO, Ramez was a managing director at Accenture for more than 29 years, working with government and non-government clients to deliver large-scale transformational change, in particular with innovative, technological business solutions. In this episode of Culture Makers Ramez and I chat about the transformation challenge, how to influence and evolve culture in a new role, the importance of continuous innovaton and more! ---------------- Find out more about Colin: www.colindellis.com Join the Culture Makers Community: www.culturemakers.community Music courtesy of https://www.purple-planet.com --- Send in a voice message: https://anchor.fm/culturemakers/message
Today is World Refugee Day.. Waikato is one of the biggest refugee centres in Aotearoa, and over a hundred refugees in the Waikato are currently studying at Wintec. Among those improving their English through study, is Ramez Sharfo.
Chris Caldwell in Conversation with RAMEZ NASSER, entrepreneur, lawyer and Board Member at Energisme., ...by 2035, the world will generate over 2500 zettabytes of data, requiring new technologies to be able to make use of that data, especially in the energy space, which is one of the areas that accumulates the most amount of data. In this episode, Ramez Nasser explains how the vast amount of data we produce on energy usage can help us reshape our cities, habits and policy on the Conversations on Climate podcast. The volume of data available will be essential to track and optimise energy performance from buildings and businesses, manage power usage in cities (for example by turning off lights in unused streets) and guiding new technology development. References: Background on SCADA SYSTEMS. https://en.wikipedia.org/wiki/SCADA 1 zettabyte of digital storage is equivalent to 1,000,000,000,000,000,000,000 [1021] bytes, 1 sextillion bytes. One Zettabyte is approximately equal to a thousand Exabytes, a billion Terabytes, or a trillion Gigabytes. Article on IoT - Internet of Things. https://www.insiderintelligence.com/insights/internet-of-things-definition/ The scope of the challenge before us is beyond that of any one individual or any one solution. So, we talk to thinkers, researchers, makers and business leaders.They discuss a diversity of ideas and solutions to the global climate and environmental issues and why they matter. Presented by Chris Caldwell and produced by UNITED RENEWABLES in association with LONDON BUSINESS SCHOOL, ALUMNI ENERGY CLUB.
The Purist, Mickey, Jordan and Ramez talk about Ryan Garcia's decision win over Tagoe, Golovkin unifying titles against Murata and an impending fight against Canelo Alvarez.Also discussed is Tank Vs Ryan, Devin Haney vs Kambosos JR, Canelo vs Bivol and who has had the bigger impact, Hearn or Warren
Take control of your financial future with a self-directed IRA. Ramez Fakhoury is vice president of the IRA Club. This recording is from Rad Diversifieds Inner Circle retreat in Las Vegas NV. At RADD investing is about so much more than flipping properties and buying cryptos. We educate our investors about the world of alternative investments. Ramez is an entrepreneur with 20 plus years of experience providing service in various settings. This includes the hospitality industry, financial services, and real estate. It's not easy to invest in real estate by yourself. If you don't have a team, things can spiral out of control. But when you find someone you can TRUST to work with, you get to stop second-guessing… and that's what you get with the Inner Circle. The Inner Circle is your opportunity to partner on real estate deals with a team of experts. We'll help you plan your investments strategically, navigate troubled waters, and avoid common investor pitfalls. The RADD Podcast: Explore Wealth is an exploration of Wealth, Finance, Business, and Entrepreneurship. Hosted by Dutch Mendenhall, founder of RAD Diversified and visionary behind the American Survivalist Project. The Topics of Discussion include Alternative Investments, Real Estate, Tax Auctions, REIT‘s and more. Episodes posted weekly, enjoy. Follow the link to view offerings https://www.sec.gov/Archives/edgar/data/1721469/000110465921144047/tm2134023d1_partiiandiii.htm Follow Me on all my social media platforms. Dutch Mendenhall Facebook: https://www.facebook.com/TheRealDutchMendenhall Instagram: https://www.instagram.com/dutchmendenhall/ YouTube: https://www.youtube.com/channel/UCXrgBGNkiphuyYeCcwXF1kw Twitter: https://twitter.com/TaxAuctionPros RAD Diversified Website: https://raddiversified.com/ Facebook: https://www.facebook.com/raddiversified Instagram: https://www.instagram.com/raddiversified/ YouTube: https://www.youtube.com/channel/UC3YSsFzsXLksebTwZtxL97Q American Survivalist Project Website: https://americansurvivalistproject.com/ Facebook: https://www.facebook.com/AmericanSurvivalistProject Instagram: https://www.instagram.com/americansurvivalistproject/ YouTube: https://www.youtube.com/c/americansurvivalistproject
The Purist, Jordan and Ramez breakdown Leigh Woods stoppage victory over Michael Conlan and much more
The second episode of our Step 2022 series is here!Our guest is Ramez Mohamed El-Serafy, CEO of Flat6Labs, MENA region's leading seed and early stage venture capital firm.Ramez explained how it all began for Flat6Labs, from the small lab/flat number 6 in Cairo 10 years ago.Tune in to learn about:- How passionate should a founder be about their startup- Red flags to look out for when choosing the startup to invest in- Investment opportunities: What is the next big thing?Enjoy!#TheChangeOfficerCheck out Flat6Labs: https://www.flat6labs.com/CONNECT WITH US:Website - www.thechangeofficer.comInstagram - www.instagram.com/thechangeofficerLinkedIn - www.linkedin.com/company/the-chan…-officer-podcastTwitter - twitter.com/changeofficer_
When you think of startup companies advancing the state of technology, software is probably the first thing that comes to mind. But scientific breakthroughs are still coming in the world of atoms, and that's what venture capital firm Prime Movers Lab invests in. To give us a sense of their vision for the future, the VC firm put together a "https://www.primemoverslab.com/roadmap/ (Breakthrough Science Roadmap)" to describe what a life of abundance in 2050 might be like. In this episode of "Political Economy" I'm joined by Ramez Naam and Christie Iacomini from Prime Movers Lab to discuss that uplifting vision of tomorrow and how startups are working to realize it. Ramez is a computer scientist and Chief Futurist at Prime Movers Lab, while Christie is an aerospace engineer and Vice President of Engineering.
First, Jason teaches Sunday VC School: how investors work together (01:54). In this segment you will learn.: How collaboration varies across investing stages. How lead investors are determined and what their responsibilities are. The strategies you can use to win deals (Jason explains the pitch he gives to founders with options). The warning signs to watch for when working with other investors. Tactics founders can use for lower-friction fundraising. Then, Molly chats with Ramez Naam from Prime Movers Lab in a This Week in Climate Startups segment (35:10). They discuss the declining costs of renewable energy, making the choice between advancing existing technologies and inventing new ones, how science fiction can make you a better investor and more. (00:00) Jason and Molly introduce the show (01:54) Sunday VC School - how investors work together (06:53) How collaboration varies across investing stages (08:43) Odoo - Get your first app free and a $1000 credit at https://odoo.com/twist (09:49) Why seeing other late stage investors be passive in a deal is a warning sign (11:20) How raising from more investors can be actually be easier than raising from a few (15:44) Lead investor responsibilities (20:09) Fellow - Sign up and get $1000 in credits at https://fellow.app/twist (21:38) How VCs can win over founders (26:44) Do VCs get offended by what order they get into a startup? (29:16) Will investors still invest if the founder picked another VCs term sheet? (31:33) Molly and Jason introduce the next segment (33:25) Revelo - Get 20% off the first 3 months by mentioning TWIST at https://revelo.io/twist (35:10) This Week in Climate Startups - Ramez Naam (37:55) Advancing existing technologies vs. inventing new ones (42:19) Early stage climate investing (46:43) The declining costs of renewable energy (52:52) Confronting climate tech skeptics (57:06) How writing science fiction impacts Ramez's investing Check out Prime Movers Lab: https://www.primemoverslab.com/ FOLLOW Ramez: https://twitter.com/ramez FOLLOW Jason: https://linktr.ee/calacanis FOLLOW Molly: https://twitter.com/mollywood
I remember the feeling of craving intensive clinical mentorship as a new grad. I had applied to one residency, it didn't work out, but ultimately I wasn't sure the traditional residency model was right for me. Not that there is anything wrong with traditional residency, it can be great for the right person. But ultimately, they are extremely scare, competitive, and don't always align with your clinical values. Luckily, I had been doing some informal mentorship under someone I really admired, Ramez Antoun, who had been extensively trained under a diverse spectrum of approaches spanning orthopedics, PNF, pain science, and strength and conditioning. When we joked about creating our own “residency” for me to complete under him, we suddenly realized this sounded like an awesome idea. And I am forever grateful to Ramez for taking the time to construct such a thoughtful and incredible learning experience! It was such an incredible and formative experience, and my hope is that for some of you, you are able to pave your own path of what YOUR ideal clinical mentorship looks like! Hope you enjoy this episode and let us know your thoughts! Please make sure to throw Ramez a follow on IG: @neuropedics and if you would like to learn more from Ramez, please check out the following links! Neuropedics Newsletter : https://unique-author-8436.ck.page/01ee69fcf7 Neuropedics Podcast: https://open.spotify.com/show/1ig6bCzo8Wr3nOYFP2kSyh?si=fDvhBBSrQJOr7B_q270OkA ______________________________________________________ Want to get involved in our community? Join our FREE CALU Community for monthly journal clubs and bi-monthly case studies! CALU Community FB Group
If you don't even try then you're not even giving yourself a chance! Take the lessons and turn them into blessings. On this episode young entrepreneur Ramez Attia is giving game on how to be young and successful! You don't want to miss this episode no matter your age! Tap in with Ramez: Instagram: https://www.instagram.com/ramezattia/ Connect With Us: Text Me “podcast" to 4805717347 for a new positive friend https://my.community.com/millionairemacclub Tik Tok: https://www.tiktok.com/@millionairemacclub?lang=en Instagram: https://www.instagram.com/millionairemacclub/ Facebook Group: https://www.facebook.com/groups/262727048674118/ Pinterest: https://pin.it/3zE0Fzj We believe Millionaire is not defined by monetary value but by your mindset and We are helping raise consciousness and maximizing limitless potential in order to make the world better. Support this podcast
Key Takeaways:0:00 Intro1:23 Ramez talks about digitization of the Middle East economy, what it means and what he is seeing on the ground 3:40 MENA internet penetration higher than global average (https://www.statista.com/statistics/265171/comparison-of-global-and-middle-eastern-internet-penetration-rate/)5:22 Ramez shares some of the reasons why he feels that businesses are still struggling to join the digital world 7:55 100,000 UAE Golden Visas for coders: Who can apply and how (https://www.khaleejtimes.com/news/100000-uae-golden-visas-for-coders-who-can-apply-and-how)8:53 Ramez talks about what he does with his role at Facebook to get more of the SMEs online and be digital 9:30 New unicorns spike 491% to 136 in Q2, says report (https://www.zawya.com/mena/en/business/story/New_unicorns_spike_491_to_136_in_Q2_says_report-SNG_226689313/)11:10 Facebook launches #LoveLocal initiative in MENA (https://www.sme10x.com/10x-industry/facebook-launches-lovelocal-initiative-in-mena)14:22 Ramez talks about how the pandemic has been kind of a wake up call for the SMEs to go big and digitalize 17:09 Huda Beauty (https://hudabeauty.com/us/en_US/home)17:44 Will conversational commerce be the next big thing in online shopping? (https://www.economist.com/business/2021/07/10/will-conversational-commerce-be-the-next-big-thing-in-online-shopping)18:04 Ramez talks about e-commerce and c-commerce and how they are evolving in the Middle East region and what plans Facebook has towards that 22:42 Dubai 'ghost kitchen' Kitopi is adjusting to life in a pandemic (https://www.cnn.com/travel/article/ghost-kitchens-kitopi-spc-intl/index.html)27:06 Ramez talks about the transformation of Facebook in terms of the revenue structure and how it changes as the environment changes 29:15 Ramez talks about advertisements in the Middle East and if it has fully digitalized in terms of even putting the advertiser's money online 32:18 Ramez also talks about scalability and how brands are being able to scale globally thanks to platforms like Facebook especially in the Middle East 36:16 Ramez talks about what people should be focusing on in the ecosystem for them to be successful especially in the Middle East 39:15 Ramez talks about entrepreneurship and why we need to widen its definition so as to even accommodate the small businesses and what can be done to help the SMEs 42:36 Ramez talks about how Facebook balances its business goals and the social issues especially in the Middle East region Shows Mentioned:Facebook: https://www.facebook.com/ Instagram: https://www.instagram.com/ WhatsApp: https://www.whatsapp.com/?lang=en Messenger: https://www.messenger.com/ MENA Region: https://en.wikipedia.org/wiki/MENA Huda Beauty: https://hudabeauty.com/us/en_US/home WeChat: https://www.wechat.com/ Quotes Mentioned:“If we want to evolve the general wellness and well-being of communities in our part of the world, we must significantly invest in enabling, equipping, and supporting micro, small and medium enterprises.”“The lifeblood of communities in our part of the world is the micro small and medium enterprises.”“Covid-19 forced us to rethink the power of digital connectivity out of existential need.”“Our journey is only 1% complete.”“The only thing standing in our way is ourselves.”“The pessimist may be right, but the optimist will be rich.”“Failure is the path to success.”“We have to invest in our small and medium businesses.”“70% of job growth in the US comes from SMEs.”“Half the battle is just getting out of everybody's way.”“Throwing money at the problem is not the issue.”“Be committed to learning, improving, evolving.”Guests Social Media Links: LinkedIn: https://www.linkedin.com/in/ramez-shehadi-0b395512/?originalSubdomain=ae Website: https://www.facebook.com/business/m/sharedbyfacebook/viewpoints/ramez-shehadi
In this week's episode, we sit down with Ramez Fakhoury, Vice President of the IRA Club. Ramez is an entrepreneur with 20 plus years of experience providing service in various settings. This includes the hospitality industry, financial services, and real estate. As the VP of the IRA Club, his mission is to open the doors and create the opportunity by educating, inspiring, and allowing their investors to diversify outside what others are doing. One of his favorite quotes goes, As a wise man once said, "He who is not in control of his money is not in control of his destiny." Ramez believes that offering a first-class customer service experience can help individuals take back control of their retirement. Website https://www.iraclub.org/ Resource Center https://www.iraclub.org/resources Investors Kit ($1) https://www.iraclub.org/ira-club-investors (USE PROMOCODE RAD) How to Invest with $1 Kit PDF https://drive.google.com/file/d/1eZ156W9HGh976ImnTeA3ubZinucgv7VB/view?usp=sharing Hard Money with Dutch Mendenhall is a podcast that aims to showcase those in the world of finance and entrepreneurialism. The goal of this podcast is to get to know Dutch and our guests on a more personal level while allowing them to give you insight into the world they live in, how they got there, as well as what they can do for you. Follow Me on all my social media platforms. Dutch Mendenhall Facebook: https://www.facebook.com/TheRealDutchMendenhall Instagram: https://www.instagram.com/dutchmendenhall/ Twitter: https://twitter.com/TaxAuctionPros RAD Diversified Website: https://raddiversified.com/ Facebook: https://www.facebook.com/raddiversified YouTube: https://www.youtube.com/channel/UC3YSsFzsXLksebTwZtxL97Q American Survivalist Project Website: https://americansurvivalistproject.com/ Facebook: https://www.facebook.com/AmericanSurvivalistProject Instagram: https://www.instagram.com/americansurvivalistproject/ YouTube: https://www.youtube.com/c/americansurvivalistproject The Economic Activist Website: https://economicactivist.com/ #realestateinvesting #taxauctioninvesting #realestateeducation #taxliens, #taxdeeds #wealthbilding #retirement #generationalwealth #passiveincome #REIT #investing #investment
Is economic growth compatible with environmentalism? One key to answering this question is clean, renewable energy. The cheaper it becomes, the easier it is to reduce our impact on the planet while still raising living standards for people around the world. So what does the future of the energy industry look like? How affordable have solar and wind energy become? And how should that influence our willingness to embrace a more optimistic vision for humanity? Today's episode discusses these questions with Ramez Naam. Ramez is a computer scientist and futurist, as well as the Energy and Environment Co-Chair at Singularity University. He is also the author of the https://www.amazon.com/Nexus-Trilogy-Book-1-ebook/dp/B00TOZI7FM (Nexus trilogy), an award-winning science fiction series that explores how neurotechnology could impact our society.
In the premiere episode of Privacy is the New Celebrity, MobileCoin founder Josh Goldbard interviews author and technologist Ramez Naam. Ramez is best known as the author of The Nexus Trilogy, but his current focus is clean energy technology with an emphasis on solar energy. Josh and Ramez discuss drones, AI, the 4th amendment, and the relationship between privacy and creativity. They also share stories from the first time they each realized privacy was important, and that one time Ramez got a cult for his birthday.
People want control over their money, especially their retirement savings. There are so many companies like Fidelity, Vanguard, or Schwab that offer 401k retirement plans or self-directed IRAs but they are not fully in your control. That is why Ramez Fakhoury and Kasia Macioch are here today to tell you all about The IRA Club. Ramez is an entrepreneur and is the Vice President of The IRA Club. Kasia, who works with Ramez in The IRA Club, has spent the last several years assisting thousands of IRA Club clients set up their accounts and where to invest. Join your hosts, Jay Tenenbaum & Seti Gershberg as they learn a thing or two about the benefits of a self-directed IRAs in real estate, the difference between an IRA, 401k, and a Roth, how the IRA Club differentiates itself from the competition, and many more. Listen in if you want to make the most out of your retirement funds.Links and Resources:Learn more about Ramez Fakhoury.Learn more about Kasia Macioch.Learn more about The IRA Club.Learn more about Scottsdale REI.Learn more about Seti Gershberg and Jay Tenenbaum.Learn more about podcast sponsor REIBLADE at reiblade.com.Love the show? Subscribe, rate, review, and share! https://www.remastermind.live/
© 2020-2025 Ivy Podcast Discovery LLC
